Jefferies Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $90

Benzinga Newsdesk www.benzinga.com Negative 53.9%

Neg 53.9% Neu 0% Pos 0%

Jefferies analyst Akash Tewari maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and lowers the price target from $113 to $90.